Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

Wedzicha J. A., Banerji D., Chapman K. R., Vestbo J., Roche N., Ayers T., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.374, sa.23, ss.2222-2234, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 374 Sayı: 23
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1056/nejmoa1516385
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2222-2234
  • Ankara Üniversitesi Adresli: Hayır

Özet

BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.